

Effective Date: 07/01/2024
Reviewed: 4/2024
Scope: Medicaid

## Rexulti (brexpiprazole)

### POLICY

#### I. INDICATIONS

Rexulti is indicated for:

- Adjunctive treatment of major depressive disorder (MDD) in adults.
- Treatment of schizophrenia in adults and pediatric patients ages 13 years and older
- Treatment of agitation associated with dementia due to Alzheimer’s disease

Limitations of Use: Rexulti is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease

#### II. CRITERIA FOR APPROVAL

An authorization of 12 months may be granted when all the following criteria are met:

##### Schizophrenia

- A. The member is being treated for schizophrenia; AND
- B. The member has experienced a failure, contraindication, or intolerance to at least three formulary atypical antipsychotics (e.g., aripiprazole, olanzapine, quetiapine IR or ER, risperidone, or ziprasidone)

##### Major Depressive Disorder (MDD)

- A. The member is being treated for adjunctive therapy for the treatment of MDD; AND
- B. The member has experienced a failure, contraindication or intolerance to aripiprazole

##### Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease

- A. The member is being treated for agitation associated with dementia due to Alzheimer’s disease; AND
- B. The member has experienced a failure, contraindication, or intolerance to at least one formulary selective serotonin reuptake inhibitor; AND
- C. The member has experienced a failure, contraindication, or intolerance to at least one formulary generic atypical antipsychotic (e.g., aripiprazole, olanzapine, quetiapine IR or ER, risperidone, or ziprasidone)

#### III. CONTINUATION OF THERAPY

Rexulti will continue to pay after the initial approval if there is at least one paid claim of at least a 30-day supply within the last 365 days for Rexulti.

#### IV. QUANTITY LIMIT

Rexulti 0.25mg, 0.5mg, 1mg, 2mg, 3mg and 4mg tablets have a quantity limit of 1 tablet per day.

#### V. REFERENCES

1. Rexulti [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; May 2023.